专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US07388003B2 Δ15-D-Homosteroids with androgenic action 失效
标题翻译：具有雄激素作用的Delta15-D-类固醇激素
公开(公告)号：US07388003B2
公开(公告)日：2008-06-17
申请号：US10923080
申请日：2004-08-23
申请人： Ralf Wyrwa , Sven Ring , Guenter Kaufmann , Walter Elger , Birgitt Schneider
发明人： Ralf Wyrwa , Sven Ring , Guenter Kaufmann , Walter Elger , Birgitt Schneider
IPC分类号： A61K31/56 , C07J1/00
CPC分类号： C07J63/00 , Y10S514/841
摘要： The invention relates to Δ15-D-homosteroids of general formula (I) process for their production and pharmaceutical compositions that contain these compounds. The compounds of general formula I according to the invention have androgenic activity.
摘要翻译：本发明涉及其制备的通式（I）的三羟甲基-D-类固醇激素和含有这些化合物的药物组合物。根据本发明的通式I的化合物具有雄激素活性。

22. 发明申请

US20070179094A1 Modulation of MDL-1 activity for treatment of inflammatory disease 审中-公开
标题翻译：调节MDL-1活性治疗炎性疾病
公开(公告)号：US20070179094A1
公开(公告)日：2007-08-02
申请号：US11698449
申请日：2007-01-26
申请人： Daryl Faulds , Stefano Fiorucci , Ying-Ping Jiang , Yi Liu , John Parkinson
发明人： Daryl Faulds , Stefano Fiorucci , Ying-Ping Jiang , Yi Liu , John Parkinson
IPC分类号： A61K38/17 , C07H21/04 , C12P21/06 , C07K14/705
CPC分类号： C07K14/705 , A61K38/00 , C07K14/70503 , C07K2319/30
摘要： The present invention provides compositions and methods that modulate MDL-1 activity in a cell, in vivo or in vitro. In particular, the present invention provides methods for treatment of inflammatory diseases using synthetic or recombinant compositions that modulate MDL-1 activity in a mammalian cell, in vivo or in vitro. More particularly, the present invention provides protein compositions useful for the treatment of diseases having an inflammatory process mediated by MDL-1.
摘要翻译：本发明提供了在体内或体外调节细胞中MDL-1活性的组合物和方法。特别地，本发明提供使用在哺乳动物细胞中体内或体外调节MDL-1活性的合成或重组组合物治疗炎性疾病的方法。更具体地，本发明提供了可用于治疗由MDL-1介导的炎性过程的疾病的蛋白质组合物。

23. 发明授权

US07250408B2 Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility 失效
标题翻译：糖皮质激素受体拮抗剂用于预防和治疗糖皮质激素介导的性腺机能减退症，性功能障碍和/或不育症
公开(公告)号：US07250408B2
公开(公告)日：2007-07-31
申请号：US10735487
申请日：2003-12-12
申请人： Ulrich Bothe , Gerd Schubert , Guenter Kaufmann , Lothar Sobek , Vladimir Patchev , Alexander Hillisch
发明人： Ulrich Bothe , Gerd Schubert , Guenter Kaufmann , Lothar Sobek , Vladimir Patchev , Alexander Hillisch
IPC分类号： A61K31/56 , C07J1/00
CPC分类号： A61K31/00 , A61K31/567 , A61K31/573 , C07J1/00
摘要： The novel glucocorticoid receptor antagonists are 11β-substituted steroid compounds of formula (I): wherein R1 denotes a methyl group, a methoxy group, or an ethoxy group; wherein R2 denotes a tert.-butyl group, a 1-hydroxy-1-methylethyl group, a 1-methoxy-1-methylethyl group, an ethyl isocrotonate group, or a substituted phenyl group. The method of treating an individual suffering from glucocorticoid-mediated hypogonadism, sexual dysfunctions, and/or infertility includes administering a daily dosage consisting of an effective amount of one of these 11β-substituted steroid compounds.
摘要翻译：新型糖皮质激素受体拮抗剂是式（I）的11b取代的类固醇化合物：其中R 1表示甲基，甲氧基或乙氧基; 其中R 2表示叔丁基，1-羟基-1-甲基乙基，1-甲氧基-1-甲基乙基，异巴豆酸乙酯基或取代的苯基。治疗患有糖皮质激素介导的性腺机能减退，性功能障碍和/或不孕症的个体的方法包括施用由有效量的这些11b取代的类固醇化合物之一组成的每日剂量。

24. 发明授权

US07250168B2 Tissue factor targeted thrombomodulin fusion proteins as anticoagulants 失效
标题翻译：组织因子靶向血栓调节蛋白融合蛋白作为抗凝剂
公开(公告)号：US07250168B2
公开(公告)日：2007-07-31
申请号：US10427805
申请日：2003-04-30
申请人： David Light , Kirk McLean
发明人： David Light , Kirk McLean
IPC分类号： A61K39/00
CPC分类号： C07K16/36 , A61K38/00 , A61K48/00 , A61K2039/505 , C07K14/485 , C07K14/7455 , C07K16/40 , C07K19/00 , C07K2317/21 , C07K2317/32 , C07K2317/622 , C07K2319/00
摘要： This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
摘要翻译：本发明涉及新颖的融合蛋白，其由结合组织因子（TF）的靶向蛋白组成，其与单独的血栓调节蛋白EGF456结构域或与至少一种其它TM结构域可操作地连接，所述TM结构域选自的N末端疏水区域，EGF123结构域，EGF3和EGF4之间的域间环和O-糖基化的Ser / Thr富集结构域，或其类似物，片段，衍生物或变体。融合蛋白在损伤位点处结合并防止血栓形成的发生。融合蛋白可用于治疗各种血栓形成病症，包括但不限于深静脉血栓形成，弥散性血管内凝血和急性冠状动脉综合征。

25. 发明授权

US07208283B2 Methods for determining hormonal effects of substances using Ewing sarcoma protein and androgen receptor 失效
标题翻译：使用尤文肉瘤蛋白和雄激素受体测定物质激素作用的方法
公开(公告)号：US07208283B2
公开(公告)日：2007-04-24
申请号：US10791017
申请日：2004-03-02
申请人： Maik Obendorf , Siegmund Wolf
发明人： Maik Obendorf , Siegmund Wolf
IPC分类号： G01N33/567 , C07K14/72 , C12N5/16 , C12N15/09 , C12N15/63
CPC分类号： G01N33/6875 , G01N33/74 , G01N33/743 , G01N2500/02 , G01N2500/10
摘要： In the method of determining hormonal effects of substances, a test substance is contacted with Ewing sarcoma protein (EWS) or a derivative of it and with an androgen receptor (NR) or a derivative of it; and the effect of the test substance on binding of EWS with the androgen receptor or its derivative or on ligand-induced activity of the androgen receptor is determined, preferably in a cellular system. A method for determining interference in the co-modulator mechanism between androgen receptor and EWS, which includes measurement of androgen receptor and EWS concentrations, is described. A method for identification and characterization of substances that influence the activity of a nuclear receptor, especially androgen receptor, using EWS or a derivative of it is disclosed.
摘要翻译：在确定物质激素作用的方法中，将测试物质与尤文肉瘤蛋白（EWS）或其衍生物与雄激素受体（NR）或其衍生物接触; 测定物质对雄激素受体或其衍生物的结合与雄激素受体的配体诱导活性的影响，优选在细胞系统中测定。描述了确定雄激素受体和EWS之间共调节机制干扰的方法，其包括雄激素受体和EWS浓度的测量。公开了使用EWS或其衍生物来鉴定和表征影响核受体，特别是雄激素受体活性的物质的方法。

26. 发明授权

US3928615A Method of protecting seeds and plants against fungi 失效
标题翻译：保护种子和植物免于真菌的方法
公开(公告)号：US3928615A
公开(公告)日：1975-12-23
申请号：US44441074
申请日：1974-02-21
申请人： SCHERING AG
发明人： NUSSLEIN LUDWIG , RODER KURT , PIEROH ERNST ALBRECHT
IPC分类号： A01N20060101 , A01N43/82 , A01N43/824 , C07D285/12 , C07D417/04 , A01N9/00 , A01N9/22
摘要： 2-(4-Pyridyl)-5-alkylsulfinyl-1,3,4-thiadiazoles and the sulfonyl analogs thereof have strong fungicidal effects combined with low toxicity to crop plants.
摘要翻译： 2-（4-吡啶基）-5-烷基亚磺酰基-1,3,4-噻二唑及其磺酰基类似物具有强烈的杀真菌作用以及对作物的低毒性。

27. 发明授权

US3925473A Herbicidal oxime esters of phenoxyalkanoic esters and their use as selective herbicides 失效
标题翻译：苯氧基烷酸酯的除草肟酯及其作为选择性除草剂的用途
公开(公告)号：US3925473A
公开(公告)日：1975-12-09
申请号：US42400573
申请日：1973-12-12
申请人： SCHERING AG
发明人： NUSSLEIN LUDWIG , ARNDT FRIEDRICH
IPC分类号： C07C131/00
CPC分类号： C07D213/63
摘要： Oxime esters of phenoxyalkanoic acids, having a common core of the formula

WHEREIN R1 and R2 individually or jointly are hydrocarbyl or substituted hydrocarbyl, R3 is hydrogen or lower alkyl, and the phenyl group carries up to three substituents, are herbicides harmless to cereal crops at application rates at which they destroy or at least severely damage numerous common weeds, including millets, which are intermingled with the crop plants.
摘要翻译：具有式WHEREIN R 1和R 2的共同核心的苯氧基烷酸的肟酯单独或共同地是烃基或取代的烃基，R 3是氢或低级烷基，苯基最多可带有三个取代基，是对谷类作物无害的除草剂它们破坏或至少严重损害与作物混合的许多常见杂草（包括小麦）的施用率。

28. 发明授权

US3925173A Electrocatalytic hydrogenation process 失效
标题翻译：电化学加氢工艺
公开(公告)号：US3925173A
公开(公告)日：1975-12-09
申请号：US46617274
申请日：1974-05-02
申请人： SCHERING AG
发明人： JUNGHANS KLAUS
IPC分类号： C07J1/00 , C07J15/00 , C25B3/04 , C07C167/12 , C07C169/00
CPC分类号： C25B3/04 , C07J1/007 , C07J1/0085 , C07J1/0092 , C07J15/00
摘要： Steroids having a multiple carbon-carbon bond which is isolated or conjugated with an aromatic ring and which are hydrogenatable to a mixture of stereoisomers are stereo-specifically and selectively reduced by electrocatalytic hydrogenation in an acidic solvent employing a cathode whose surface is a finely divided metal hydrogenation catalyst, such as Raney nickel or palladium.

29. 发明授权

US3920682A Benzimidazole-1-carboxylic acid amides 失效
标题翻译：苯并咪唑-1-羧酸
公开(公告)号：US3920682A
公开(公告)日：1975-11-18
申请号：US50380774
申请日：1974-09-06
申请人： SCHERING AG
发明人： RODER KURT , PUTTNER REINHOLD , PIEROH ERNST-A
IPC分类号： A01N47/38 , A01M20060101 , A01N20060101 , A01N47/18 , A01P3/00 , C07C20060101 , C07D20060101 , C07D235/00 , C07D235/04 , C07D235/14 , C07D235/20 , C07D235/32 , C07D239/00 , C07D307/00 , C07D307/14 , C07D307/32 , C07D333/36 , C07D405/12 , C07D407/12 , C07D409/12
CPC分类号： C07D405/06
摘要： Benzimidazole-1-carboxylic acid amides and their method of production are provided for use per se or in fungicidal combinations.

30. 发明授权

US3920528A Bright acid zinc plating method and electrolyte 失效
标题翻译：明亮的酸性镀锌方法和电解液
公开(公告)号：US3920528A
公开(公告)日：1975-11-18
申请号：US40969473
申请日：1973-10-25
申请人： SCHERING AG
发明人： VOSS GUNTER , HOFFMANN HELGA
IPC分类号： C25D3/22
CPC分类号： C25D3/22
摘要： Bright zinc electrodeposits are obtained at high current densities from aqueous, acid electrolytes containing zinc ions, inert alkali metal salts of strong mineral acids for improving conductivity, and a brightener which includes a small amount of an acid having a carboxyl group or a sulfo group attached directly or through a lower alkylene, vinyl, carbonyl, or phenylene group to the heterocyclic ring of pyridine, quinoline, isoquinoline, pyrrol, piperidine, pyrrolidine, or pyrrolidone. The electrolytes are free from significant amounts of complexing agents that would impede precipitation of the zinc ions at weakly alkaline pH so that the electrolytes do not present a waste disposal problem.
摘要翻译：以含有锌离子的水性酸性电解质，强无机酸的惰性碱金属盐，改善导电性的高电流密度获得明亮的锌电沉积物，以及包含少量具有羧基或磺基的酸的增白剂吡啶，喹啉，异喹啉，吡咯，哌啶，吡咯烷或吡咯烷酮等杂环的低级亚烷基，乙烯基，羰基或亚苯基。电解质不含显着量的络合剂，其将在弱碱性pH下阻止锌离子的沉淀，使得电解质不会产生废物处理问题。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式